OAM
LRMR icon

Oxford Asset Management’s Larimar Therapeutics LRMR Stock Holding History

Oxford Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,155
Closed -$170K – 1941
2019
Q3 		$170K Sell
19,155
-7,454
-28% -$81.7K ﹤0.01% 1591
2019
Q2 		$380K Buy
26,609
+12,823
+93% +$342K 0.01% 1376
2019
Q1 		$453K Sell
13,786
-10,583
-43% -$543K 0.01% 1262
2018
Q4 		$1.45M Buy
24,369
+2,503
+11% +$247K 0.04% 663
2018
Q3 		$3.07M Buy
21,866
+9,190
+72% +$1.12M 0.06% 424
2018
Q2 		$1.48M Sell
12,676
-2,657
-17% -$226K 0.03% 840
2018
Q1 		$1.37M Buy
15,333
+3,159
+26% +$268K 0.03% 779
2017
Q4 		$679K Sell
12,174
-2,085
-15% -$94K 0.01% 1088
2017
Q3 		$585K Buy
14,259
+5,616
+65% +$234K 0.01% 1143
2017
Q2 		$364K Buy
+8,643
New +$442K 0.01% 1199
2016
Q2 		– Sell
-2,049
Closed -$164K – 846
2016
Q1 		$164K Sell
2,049
-17,648
-90% -$1.39M ﹤0.01% 726
2015
Q4 		$1.5M Buy
+19,697
New +$3.16M 0.04% 450

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Oxford Asset Management's LRMR Position: Q4 2019 in Review

Oxford Asset Management sold out of Larimar Therapeutics (LRMR) in Q4 2019, closing a stake of 19,155 shares — an estimated $170K sold.

Oxford Asset Management first reported a position in LRMR in Q4 2015 and held it in 12 quarters. The position peaked at $3.07M in Q3 2018. 49 funds tracked by Wall St. Rank hold LRMR as of Q4 2019.

  • Oxford Asset Management reported no remaining Larimar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Oxford Asset Management sold 19,155 Larimar Therapeutics shares in Q4 2019, an estimated $170K.
  • Oxford Asset Management first reported a position in Larimar Therapeutics in Q4 2015 and held it in 12 quarters.
  • Oxford Asset Management's Larimar Therapeutics position peaked at $3.07M in Q3 2018.
  • 49 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.